Breast Cancer/apollohospitals.com
Dec 16, 2024, 19:10
Neoadjuvant durvalumab improves survival in early TNBC independent of pathological complete response
Akhil Santhosh, Medical Oncologist at Dr BR Ambedkar Institute Rotary Cancer Hospital, shared a post on X:
- Small randomised phase 2 trial
- Used durva only in neoadjuvant phase with nab pacli and dose dense EC
Authors: A. Schneeweiss, J. Huober, M. Braun, J. Rey, J.-U. Blohmer, J. Furlanetto, D.-M. Zahm, C. Hanusch, J. Thomalla, C. Jackisch, P. Staib, T. Link, K. Rhiem, C. Solbach, P.A. Fasching, V. Nekljudova, C. Denkert, M. Untch.
- One seperate window cohort where single dose of durva given 2 weeks prior
- Primary endpoint point was PCR, study was heavily powered for the same, which was not met(insignificant increase)
- Improved Disease-Free Survival, DDFS and Overall Survival, but all are exploratory analyses with no relevant meaning
- Improvement in path Cr irrespective of PDL1 expression, Residual Stromal TILS prognostic for improved IDFS .”
A. Schneeweiss
Akhil Santhosh
Breast Cancer
C. Denkert
C. Hanusch
C. Jackisch
C. Solbach
cancer
D.-M. Zahm
DDFS
Disease-Free Survival (DFS)
Durva
IDFS
J. Furlanetto
J. Huober
J. Rey
J. Thomalla
J.-U. Blohmer
K. Rhiem
M. Braun
M. Untch
OncoDaily
Oncology
Overall survival (OS)
P. Staib
P.A. Fasching
pCR
PDL1 expression
S. Loibl
T. Link
TILs
V. Nekljudova
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 16, 2024, 19:07
Dec 16, 2024, 19:00
Dec 16, 2024, 18:45
Dec 16, 2024, 18:20
Dec 16, 2024, 17:51